surinabant
Surinabant (SR147778) is a cannabinoid receptor type 1 antagonist developed by Sanofi-Aventis. It is being investigated as a potential treatment for nicotine addiction, to assist smoking cessation. It may also be developed as an anorectic drug to assist with weight loss, however there are already several CB1 antagonists or inverse agonists on the market or under development for this application, so surinabant is at present mainly being developed as an anti-smoking drug, with possible application in the treatment of other addictive disorders such as alcoholism. Other potential applications such as treatment of ADHD have also been proposed. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 2004 (NCT00239174)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cannabinoid CB1 receptorANTAGONIST
CNR1 antagonist
Chemistry & pharmacology
SMILES
CCc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Br)cc1- Mol. weight
- 522.27 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSurinabant ↗
- ChEMBLCHEMBL189676 ↗
Also known as
- 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n-(1-piperidinyl)-1h-pyrazole-3-carboxamide
- sr147778
- sr147778
- sr147778
- sr 147778
- sr-147778
- sr-147778
- sr-147778
- surinabant
- surinabant
- surinabant
- surinabant
- surinabant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00432575 | Phase 2 | Jan 1, 2007 | Sanofi |
| NCT00239174 | Phase 2 | Nov 1, 2004 | Sanofi |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 2 | 2 | 1 | 2004 |